European Pharmaceutical Manufacturer sat down with John McDermott, VP scientific consulting at Quotient Sciences, to explore how Translational Pharmaceutics is reshaping the journey from preclinical development to first-in-human studies.
How does Quotient Sciences’ integrated approach to drug development, Translational Pharmaceutics, expedite the transition from preclinical development to clinical testing?